

**We Claim:**

1. A compound selected from the group consisting of:

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino) imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.

2. 2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof.

3. 2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof.

4. A compound selected from the group consisting of:

(a) 2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

(b) 2-(2-methyl-3-phthalimidophenylimino)imidazolidine,

(c) 2-(3-acetylamino-6-chlorophenylimino)imidazolidine,

(d) 2-(3-amino-2-methylphenylimino)imidazolidine,

(e) 2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,

(f) 2-(3-amino-4-methylphenylimino)imidazolidine,

- (g) 2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (h) 2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,
- (i) 2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine, and
- (j) 2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(5-amino-2-chloro-4-dimethylamino-2-methylphenylimino)imidazolidine, and

2-(3-amino-2-methylphenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof, and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

6. A pharmaceutical composition comprising 2-(3-dimethylamino-2-methylphenylimino)imidazolidine, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

7. A pharmaceutical composition comprising a compound in accordance with claim 2, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

8. A pharmaceutical composition comprising a compound in accordance with claim 3, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

9. A pharmaceutical composition comprising:

(a) a compound selected from the group consisting of:

2-(3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(2-methyl-3-phthalimidophenylimino)imidazolidine,

2-(3-acetylamino-6-chlorophenylimino)imidazolidine,

2-(3-amino-2-methylphenylimino)imidazolidine,

2-(3-amino-4,6-dibromo-2-methylphenylimino)imidazolidine,

2-(3-amino-4-methylphenylimino)imidazolidine,

2-(4,6-dibromo-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(4-bromo-3-dimethylamino-2-methylphenylimino)imidazolidine,


2-(6-chloro-3-dimethylamino-2-methylphenylimino)imidazolidine,

2-(6-chloro-3-phthalimidophenylimino)imidazolidine,

or a pharmaceutically acceptable salt thereof; and

(b) one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

10. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>3-6</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, fluorine, bromine, iodine, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;


R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>4</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

11. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl, C<sub>1-4</sub>-alkoxy, fluorine, bromine, iodine, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;


R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C<sub>1-4</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>4</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, or halogen; and,

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C<sub>1-4</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

12. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl, C<sub>1-3</sub>-alkoxy, fluorine, bromine, iodine, or -CF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;


R<sup>3</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, C<sub>1-3</sub>-alkoxy, halogen, or -CF<sub>3</sub>;

R<sup>4</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, C<sub>1-3</sub>-alkoxy, halogen, or -CF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

13. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, fluorine, bromine, or iodine;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, methyl, fluorine, chlorine, or bromine;

$R^4$  is hydrogen; and

$R^5$  is hydrogen, methyl, chlorine, or bromine;

or a pharmaceutically acceptable salt thereof.


14. A pharmaceutical composition comprising a compound in accordance with claim 10, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

15. A pharmaceutical composition comprising a compound in accordance with claim 11, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

16. A pharmaceutical composition comprising a compound in accordance with claim 12, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

17. A pharmaceutical composition comprising a compound in accordance with claim 13, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

18. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>3-6</sub>-cycloalkyl, C<sub>1-6</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form a 5- or 6-membered, saturated or unsaturated ring containing 0, 1, or 2 additional heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, wherein each additional nitrogen atom is unsubstituted or substituted by methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or *tert*-butyl, or R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;

R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;


R<sup>4</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, or hexyl; and

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, pentyl, hexyl, C<sub>1-6</sub>-alkoxy, fluorine, bromine, iodine, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

19. A compound of the formula (II)





wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, cyclopropyl, C<sub>1-4</sub>-alkoxy, halogen, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>2</sup> is -NR<sup>6</sup>R<sup>7</sup>, wherein R<sup>6</sup> and R<sup>7</sup> together with the nitrogen between them form phthalimido;


R<sup>3</sup> is hydrogen, halogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C<sub>1-4</sub>-alkoxy, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

R<sup>4</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, or halogen; and,

R<sup>5</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, *tert*-butyl, C<sub>1-4</sub>-alkoxy, fluorine, bromine, iodine, -CF<sub>3</sub>, or -OCF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.

20. A compound of the formula (II)



wherein:

R<sup>1</sup> is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, cyclopropyl, C<sub>1-3</sub>-alkoxy, halogen, or -CF<sub>3</sub>;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;


$R^3$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, halogen, or  $-CF_3$ ;

$R^4$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, or halogen; and,

$R^5$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl,  $C_{1-3}$ -alkoxy, fluorine, bromine, iodine, or  $-CF_3$ ;

or a pharmaceutically acceptable salt thereof.

21. A compound of the formula (II)



wherein:

$R^1$  is hydrogen, methyl, ethyl, *n*-propyl, isopropyl, or halogen;

$R^2$  is  $-NR^6R^7$ , wherein  $R^6$  and  $R^7$  together with the nitrogen between them form phthalimido;

$R^3$  is hydrogen, methyl, fluorine, chlorine, or bromine;

$R^4$  is hydrogen; and

$R^5$  is hydrogen, methyl, fluorine, or bromine;

or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition comprising a compound in accordance with claim 18, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

23. A pharmaceutical composition comprising a compound in accordance with claim 19, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

24. A pharmaceutical composition comprising a compound in accordance with claim 20, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.

25. A pharmaceutical composition comprising a compound in accordance with claim 21, and one or more pharmaceutically acceptable excipients, adjuvants, carriers, or preservatives.